Long-term remission in a patient with erythroleukemia following interferon-alpha treatment.

Abstract

A patient in second relapse of acute erythroleukemia (AEL) was treated with 10 MU of recombinant interferon (IFN)-alpha subcutaneously for 24 days after he had failed standard chemotherapy. Besides fever up to 38.9 degrees C and a transient raise in liver function parameters, treatment was well tolerated but had to be discontinued because of a severe decrease in white blood cell and platelet count. After termination of IFN treatment, both cell populations showed a continuous rise during the following weeks and hemoglobin increased concomitantly. Partial remission could be reached as was demonstrated by a decrease in PAS-positive erythroblasts in bone marrow biopsy. Further studies with IFN in patients with AEL refractory to cytostatic chemotherapy are recommended.

• Authors: G G Steger, C Dittrich, A Chott, K Derfler, J D Schwarzmeier
• Journal: Journal of biological response modifiers (J Biol Response Mod) Vol. 8 Issue 4 Pg. 351-4 (Aug 1989) ISSN: 0732-6580 [Print] United States
• PMID: 2754435 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon Type I
• Recombinant Proteins

Topics

• Adult
• Humans
• Interferon Type I (therapeutic use)
• Leukemia, Erythroblastic, Acute (drug therapy)
• Male
• Recombinant Proteins
• Remission Induction